Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease, is a spectrum of liver injury characterized by increased hepatocellular fat deposition with different histological degrees of severity. Simple fat accumulation above 5 % (MASL – Metabolic-dysfunction associated steatotic liver) in the absence of features of liver damage is a relatively benign, non-progressive disease. On the contrary, a superimposed liver inflammation and apoptosis (MASH – Metabolic-dysfunction associated steatohepatitis), in particular when associated with increased scar tissue deposition, is a hallmark of progressiveness of MASLD with a relevant impact on prognosis and disease burden [1].
